US Patent

US10525045 — Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones

Method of Use · Assigned to Amicus Therapeutics Inc · Expires 2028-04-28 · 2y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects dosing regimens for administering pharmacological chaperones to treat disorders caused by improper protein misfolding.

USPTO Abstract

The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.

Drugs covered by this patent

migalastat-hydrochloride (MIGALASTAT HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2371`	—	migalastat-hydrochloride

Patent Metadata

Patent number: US10525045
Jurisdiction: US
Classification: Method of Use
Expires: 2028-04-28
Drug substance claim: No
Drug product claim: No
Assignee: Amicus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.